References
- Hanauer SB. Management of Crohn's disease in adults. Am J Gastroenterol 2001;96(3): 635–43
- Salomon P, Kornbluth A, Aisenberg J, et al. How effective are current drugs for Crohn's disease? A meta-analysis. J Clin Gastroenterol 1992;14(3): 211–5
- Warner AS, MacDermott RP. Update on the treatment of inflammatory bowel disease. Resid Staff Physician 1997 July;43(7): 11–3
- Sutherland L, Singleton J, Sessions J, et al. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 1991;32:1071–5
- Colombel JF, Lémann M, Cassagnou M, et al. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Am J Gastroenterol 1999;94(3): 674–8
- Duffy LF, Daum F, Fisher SE, et al. Peripheral neuropathy in Crohn's disease patients treated with metronidazole. Gastroenterology 1985;88(3): 681–4
- Hanauer SB. Inflammatory bowel disease. N Engl J Med 1996;334(13): 841–8
- Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984; 86(2): 249–66
- Löfberg R, Danielsson A, Suhr O, et al. Oral budesonide versus prednisolone in patients with active extensive left-sided ulcerative colitis. Gastroenterology 1996;110(6): 1713–8
- Sands BE. Therapy of inflammatory bowel disease. Gastroenterology 2000;118(2 Suppl 1):S68–82
- Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's disease cA2 Study Group. N Engl J Med 1997;337(15): 1029–35
- Rutgeerts P, d'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117(4): 761–9
- Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340(18): 1398–405
- Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345(15): 1098–104
- Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol 1996;91(3): 423–33
- Vasiliauskas EA. Monoclonal antibody therapy in inflammatory bowel disease. In: Bistrian BR, Walker-Smith JA, eds. Inflammatory bowel diseases. Nestle Nutrition Workshop Series Clinical and Performance Programme. Series 2. Basel: Vevey, 1999:237–55
- Lichtenstein G, Bao W, Keenan G, et al. Infliximab treatment allows Crohn's disease to reduce or discontinue concomitant corticosteroid use: ACCENT 1-year results. (Abstr) Gastroenterology 2002;122(4):A–615